Recently, Zhuhai Trinomab Pharmaceutical Co., Ltd（Trinomab） has successfully obtained two international certificates- the ISO14001 Environmental Management System Certificate and the ISO45001 Occupational Health and Safety Management System Certificate. These certificates signify the international recognition on Trinomab’s high standards on environmental protection and occupational health and safety. It reflects Trinomab's firm commitment to excellence in management in promoting sustainable development and ensuring the health of its employees.
ISO14001 Environmental Management System
ISO14001 is an international standard for environmental management systems formulated by the International Organization for Standardization (ISO). This standard requires companies to establish and implement a set of systematic management process to effectively control the impact of their activities, products and services on the environment, continuously improve environmental performance and comply with relevant legal and regulations.
Trinomab's attainment of ISO14001 certification indicates that the company has established a systematic and effective environmental management system. In the future, it will continue to optimize environmental management strategies. Through measures such as enhancing resource utilization, minimizing and purifying waste and preventing pollution, the company aims to promote green production and sustainable development while fulfilling its commitment to environmental protection through tangible actions.
ISO45001 Occupational Health and Safety Management System
As the latest international standard for occupational health and safety management, ISO45001 aims to help enterprises prevent injuries and health impairments in the workplace and provide a safe and healthy working environment for employees.
Trinomab has successfully obtained ISO45001 certificate that demonstrates that the company has established a comprehensive system for risk identification, assessment and control. It can effectively ensure safety in workplace, promote the physical and mental health of employees, and create a harmonious and stable working atmosphere. This achievement reflects Trinomab's "people-oriented" corporate culture and highlights the company's strong emphasis on employee health and safety.
Looking Ahead: Continuous Optimization
The acquisition of these 2 ISO international certificates is a new step in Trinomab's international standardized operation and management and is of great significance for the construction of environmental health and safety management. With this new starting point, Trinomab will continue to adhere to the core concept of "green development and safety first", strictly follow the requirements of the two international standards, deepen the practice of environmental and occupational health and safety management systems, continuously pursue excellent performance, commit to achieving coordinated development of economic, social and environmental benefits.
Trinomab looks forward to working together with industry partners to jointly promote the entire industry to move forward towards a greener, healthier and more sustainable future, and contribute to protecting the ecological environment and building a harmonious society.
About Trinomab
Zhuhai Trinomab Pharmaceutical is a clinical stage biopharmaceutical company with a global expansion perspective. The company is mainly engaged in R&D of innovative fully native human mAb drugs. The core technology of the company is known as the fourth-generation antibody technology HitmAb®, a proprietary technology platform featuring differentiated advantages and high efficiency for the discovery of fully native human mAbs as therapeutics against infectious diseases, autoimmune disorders, malignant tumors and other human diseases.
With the mission of “Create Clinical Value” in mind, remarkable progress has been made by Trinomab in recent years. NDA for Siltartoxatug Injection (anti-tetanus toxin monoclonal antibody) has been formally accepted in last December by China NMPA. TNM001 injection (anti-RSV long-acting monoclonal antibody) has just entered phase III clinical trials recently. TNM009 injection (anti-NGF monoclonal antibody) and TNM005 injection (anti-VZV monoclonal antibody) have entered in phase I clinical trials last year in China and the United States, respectively. Clinical trial for TNM006 injection (anti-hCMV monoclonal antibody) will be launched in the first half of the next year as the IND has been approved for TNM006 in 2023. In addition, several new products are in preparation of IND filling with additional more antibody projects on the horizon.
